TRAVERE THERAPEUTICS

Lobbying for TRAVERE THERAPEUTICS · Biopharmaceuticals

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 16, 2025

Expenses

$160,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 4

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

HR 1518
New Era of Preventing End-Stage Kidney Disease Act
HR 946
ORPHAN Cures Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 1040
A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Healt…
HR 1414
Cameron’s Law

Lobbying activity 6

Health Issues

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act

Pharmacy

HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)

Medical/Disease Research/Clinical Labs

HR 1262, S 932 Give Kids a Chance Act to renew PRV program

Medicare/Medicaid

Regulations regarding transparency, reimbursement and care, particularly regarding rare disease.

S.1040, to prohibit product hopping and for other purposes

Taxation/Internal Revenue Code

H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.